RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

4 hours ago
Pharma
FDA+

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

5 hours ago
Pharma
FDA+

Sanofi touts $20B in­vest­ment in US over five years

5 hours ago
Pharma
Manufacturing

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

5 hours ago
Pharma
FDA+

SK, Car­lyle bol­ster blue­bird bio bid; Theri­ni Bio rais­es $39M

9 hours ago
News Briefing

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

11 hours ago
Startups
Deals

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

13 hours ago
Deals
Pharma

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

13 hours ago
Deals
Pharma

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

14 hours ago
R&D
Cell/Gene Tx

Oma­da Health joins the dig­i­tal health IPO cor­ral

Yesterday
Health Tech

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Yesterday
Cell/Gene Tx
Law

HHS fo­cus­es on 'trans­paren­cy' in third-round IRA ne­go­ti­a­tion guid­ance

Yesterday
Pharma
Law

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

Yesterday
Pharma
Manufacturing

Arc­turus to pri­or­i­tize mR­NA ther­a­peu­tics in bid to boost rare dis­ease pro­grams

Yesterday
R&D

Cy­to­ki­net­ics gets an 'in­cre­men­tal' win for de­layed heart drug

Yesterday
R&D

Ax­some's $570M loan with Black­stone; Al­tim­mune makes its own cred­it deal

Yesterday
News Briefing

Unit­ed­Health Group CEO An­drew Wit­ty steps down

Yesterday
People
Health Tech

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

Yesterday
R&D

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

Yesterday
Pharma

Up­dat­ed: To spin off or not to spin off? Gala­pa­gos backpedals on sep­a­ra­tion plans, CEO Paul Stof­fels ex­its ear­ly

Yesterday
People
Cell/Gene Tx

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

Yesterday
People
Pharma

Dutch biotech gets $146M for late-stage tri­als in three meta­bol­ic dis­or­ders

Yesterday
Financing
Startups

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

2 days ago
Pharma

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

2 days ago
Pharma
Law
1234 Next page Last page
A service from the Financial Times